UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.95 Million Holdings in Tilray Inc (NASDAQ:TLRY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Tilray Inc (NASDAQ:TLRY) by 6.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,677,899 shares of the company’s stock after buying an additional 107,530 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Tilray were worth $2,953,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of TLRY. Ferguson Wellman Capital Management Inc. bought a new position in shares of Tilray during the third quarter valued at about $26,000. Signature Estate & Investment Advisors LLC bought a new position in shares of Tilray during the 2nd quarter worth approximately $29,000. Jeppson Wealth Management LLC purchased a new position in shares of Tilray in the 2nd quarter worth approximately $33,000. Vanguard Capital Wealth Advisors bought a new position in shares of Tilray in the second quarter valued at approximately $34,000. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Tilray during the second quarter valued at approximately $37,000. Institutional investors own 9.35% of the company’s stock.

Insider Buying and Selling at Tilray

In other Tilray news, CFO Carl A. Merton bought 26,000 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was bought at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the completion of the acquisition, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.87% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Separately, Roth Mkm decreased their price objective on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a report on Friday, October 11th.

Tilray Trading Down 1.7 %

NASDAQ TLRY opened at $1.19 on Friday. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08. The stock’s 50-day simple moving average is $1.48 and its two-hundred day simple moving average is $1.67. Tilray Inc has a twelve month low of $1.15 and a twelve month high of $2.97. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.41 and a beta of 2.08.

Tilray (NASDAQ:TLRY) last released its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The company had revenue of $200.00 million for the quarter, compared to analyst estimates of $218.70 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.10) EPS. Research analysts forecast that Tilray Inc will post -0.14 EPS for the current fiscal year.

Tilray Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.